Viewing data from:

CHOLESTYRAMINE

ANDA

CHOLESTYRAMINE | A211119 | AJANTA PHARMA LTD

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 2 NDCs

Highest NADAC/Unit

$0.7724

per ea

Lowest NADAC/Unit

$0.0946

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
27241013436CHOLESTYRAMINE PACKET	$0.7724	EA	Generic	—	2026-08-19
27241013451CHOLESTYRAMINE POWDER	$0.0946	GM	Generic	—	2026-08-19

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain3 active DMFs2 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

PUROLITE LLCCHOLESTYRAMINE RESIN USP

DMF 73241988

ION EXCHANGE INDIA LTDCHOLESTYRAMINE RESIN USP (INDION 454)

DMF 231712009

PHAEX POLYMERS PRIVATE LTDCHOLESTYRAMINE RESIN USP AS IN

DMF 276072013

DOW CHEMICAL COInactiveCHOLESTYRAMINE USP

DMF 57591985

ROHM AND HAAS COInactiveCHOLESTYRAMINE RESIN, USP-AMBERLITE IRP-276

DMF 65061986

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 4GM RESIN/PACKET

0 patents0 exclusivities▴

POWDER;ORAL | Approved: Apr 6, 2020

No patent or exclusivity listings for this strength.

#002 — EQ 4GM RESIN/SCOOPFUL

0 patents0 exclusivities▾

POWDER;ORAL | Approved: Apr 6, 2020